BioLife Sciences Inc.
BLFE · OTC
11/30/2020 | 11/30/2019 | 11/30/2018 | 11/30/2017 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$1 | $0 | $0 | $0 |
| % Margin | -239.3% | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$1 | $0 | -$0 | -$0 |
| % Margin | -302.2% | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$0 | -$0 | -$0 |
| % Margin | -308% | – | – | – |
| EPS | -0.025 | -0 | -0.003 | -0.077 |
| % Growth | -24,400% | 96.3% | 96.5% | – |
| EPS Diluted | -0.025 | -0 | -0.003 | -0.077 |
| Weighted Avg Shares Out | 52 | 19 | 19 | 4 |
| Weighted Avg Shares Out Dil | 52 | 19 | 19 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | $0 | -$0 | -$0 |
| % Margin | -295.9% | – | – | – |